These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28445541)

  • 1. IQGAP1 is an oncogenic target in canine melanoma.
    Lee BH; Neela PH; Kent MS; Zehnder AM
    PLoS One; 2017; 12(4):e0176370. PubMed ID: 28445541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors.
    Jameson KL; Mazur PK; Zehnder AM; Zhang J; Zarnegar B; Sage J; Khavari PA
    Nat Med; 2013 May; 19(5):626-630. PubMed ID: 23603816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas.
    Shelly S; Chien MB; Yip B; Kent MS; Theon AP; McCallan JL; London CA
    Mamm Genome; 2005 Mar; 16(3):211-7. PubMed ID: 15834638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell Proliferation.
    Crowe MS; Zavorotinskaya T; Voliva CF; Shirley MD; Wang Y; Ruddy DA; Rakiec DP; Engelman JA; Stuart DD; Freeman AK
    Mol Cancer Res; 2021 Jun; 19(6):1063-1075. PubMed ID: 33707308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quercetin suppresses the proliferation of multiple myeloma cells by down-regulating IQ motif-containing GTPase activating protein 1 expression and extracellular signal-regulated kinase activation.
    Ma Y; Jin Z; Huang J; Zhou S; Ye H; Jiang S; Yu K
    Leuk Lymphoma; 2014 Nov; 55(11):2597-604. PubMed ID: 24397597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIT Suppresses BRAF
    Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
    Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hierarchical scaffolding of an ERK1/2 activation pathway.
    Vetterkind S; Poythress RH; Lin QQ; Morgan KG
    Cell Commun Signal; 2013 Aug; 11():65. PubMed ID: 23987506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
    J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
    Cronise KE; Hernandez BG; Gustafson DL; Duval DL
    Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NRAS and BRAF mutation frequency in primary oral mucosal melanoma.
    Buery RR; Siar CH; Katase N; Gunduz M; Lefeuvre M; Fujii M; Inoue M; Setsu K; Nagatsuka H
    Oncol Rep; 2011 Oct; 26(4):783-7. PubMed ID: 21750866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma.
    Ellerhorst JA; Ekmekcioglu S; Johnson MK; Cooke CP; Johnson MM; Grimm EA
    Oncogene; 2006 Jun; 25(28):3956-62. PubMed ID: 16474847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells.
    Eskandarpour M; Kiaii S; Zhu C; Castro J; Sakko AJ; Hansson J
    Int J Cancer; 2005 May; 115(1):65-73. PubMed ID: 15688405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IQGAP1 regulates ERK1/2 and AKT signalling in the heart and sustains functional remodelling upon pressure overload.
    Sbroggiò M; Carnevale D; Bertero A; Cifelli G; De Blasio E; Mascio G; Hirsch E; Bahou WF; Turco E; Silengo L; Brancaccio M; Lembo G; Tarone G
    Cardiovasc Res; 2011 Aug; 91(3):456-64. PubMed ID: 21493702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.
    Li Y; Cheng HS; Chng WJ; Tergaonkar V
    Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14402-14407. PubMed ID: 27911794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth.
    Romeo Y; Moreau J; Zindy PJ; Saba-El-Leil M; Lavoie G; Dandachi F; Baptissart M; Borden KLB; Meloche S; Roux PP
    Oncogene; 2013 Jun; 32(24):2917-2926. PubMed ID: 22797077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis.
    Montagnani V; Maresca L; Apollo A; Pepe S; Carr RM; Fernandez-Zapico ME; Stecca B
    J Biol Chem; 2020 Nov; 295(47):16058-16071. PubMed ID: 32938713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.